The convergence of biosensing and artificial intelligence (AI) is redefining remote patient care, with next-gen bio-wearables enabling continuous molecular monitoring beyond traditional in vitro diagnostics (IVD). The latest $14 million funding round by Adaptyx Biosciences (Adaptyx) for its AI-powered bio-wearable skin patch signals growing investor confidence in technologies that could transform episodic testing into proactive, data-driven healthcare management for chronic and acute conditions alike, says GlobalData, a leading data and analytics company.
Adaptyx’s minimally invasive bio‑wearable skin patch samples interstitial fluid to track electrolytes, small molecules, hormones and cardiac biomarkers, feeding real‑time data into an AI platform that translates signals into actionable clinical guidance.
If integrated successfully into clinical workflows, Adaptyx’s technology could shift care from episodic diagnostics to continuous, proactive management that amplifies the value of existing IVD tests.
Selena Yu, Senior Medical Analyst at GlobalData, comments: “Greater patient data leads to better-informed treatment plans. By enabling continuous measurement across different health areas like metabolic, endocrine, infectious disease and oncology, these types of remote patient monitoring (RPM) can complement and extend IVD testing into monitoring treatment response between lab visits, flagging deterioration earlier, and reducing unnecessary hospital readmissions.”
Adaptyx is currently focusing developing its bio-wearable skin patch on heart failure management tracking biomarkers like NT-proBNP and creatinine, chronic kidney disease, hormone dysregulation, in-hospital monitoring, and therapeutic drug monitoring. Patients are monitored through a minimally invasive dermal probe that detects biomarkers in interstitial fluid.
Yu adds: “As Adaptyx’s technology is still in development, its full clinical reach remains to be seen. However, the patch is suited to closer monitoring of patients with chronic conditions such as cancer, chronic kidney disease and cardiac disorders. Continuous tracking of treatment response could save clinicians time and provide faster alerts for adverse reactions.”
Because the device is lightweight, unobtrusive and can be worn during daily activities, it can improve access to care for patients who struggle with bulky or intermittent monitoring systems.
Yu continues: “Also, AI‑driven analytics can support clinical decision‑making and triage patients, helping prioritise care and optimise clinician resources. The continuous monitoring aspect with a RPM device after a diagnosis with an IVD test, fills in the gaps between tests and will capture changes that typically IVD tests cannot capture.”
For example, during heart failure or a heart attack, multiple cardiac marker tests are used on a patient to continuously check their biomarker levels to monitor their condition. With the use of Adaptyx’s bio-sensor, the frequency of testing can be lowered to likely just initial testing.
Once a patient has been deemed symptomatic, a bio-sensor can be used to monitor heart failure biomarkers. Another use case example could be in companion diagnostics (CDx), as these devices are particularly valuable because they detect cancer-specific biomarkers in patient samples and thereby guide treatment selection.
Yu concludes: “These tests are typically done to determine treatment efficacy with certain patient biomarkers and can also extend to treatment monitoring. However, many of these tests lack a continuous monitoring aspect and instead rely on routine testing. Therefore, devices like Adaptyx’s, have the potential to replace testing between visits, and track treatment efficacy in real time.”
